Management of lower urinary tract dysfunction in patients with neurological disorders

Korean Journal of Urology

Volumn 53, Issue 9, 2012, Pages 583-592

  Li, Wen Ji ^a,b   Oh, Seung June ^a  

^a Seoul National University Hospital   (South Korea)

^b SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

Clean intermittent catheterization; Lower urinary tract symptoms; Nervous system diseases; Neurogenic urinary bladder; Urodynamics

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN; CHLORIDE; DOXAZOSIN; MUSCARINIC RECEPTOR BLOCKING AGENT; PHENOXYBENZAMINE; TAMSULOSIN; TERAZOSIN;

BEHAVIOR THERAPY; BLADDER SURGERY; BLURRED VISION; CEREBROVASCULAR ACCIDENT; CONSTIPATION; CYSTOSCOPY; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DIZZINESS; DROWSINESS; DRUG MECHANISM; DRY SKIN; EJACULATION DISORDER; FATIGUE; HUMAN; HYPERTENSION; LABORATORY TEST; LIFESTYLE MODIFICATION; LOWER URINARY TRACT SYMPTOM; MEDICAL HISTORY; MICTURITION; MUCOSAL DRYNESS; NEUROLOGIC DISEASE; NOSE OBSTRUCTION; PERIPHERAL NEUROPATHY; PHYSICAL EXAMINATION; POSTURAL HYPERTENSION; POSTVOID RESIDUAL URINE VOLUME; QUALITY OF LIFE; REVIEW; SPINAL CORD DISEASE; SUPRAPUBIC CATHETERIZATION; URINARY FREQUENCY; URODYNAMICS; UROFLOWMETRY; XEROSTOMIA;

EID: 84866995893     PISSN: 20056737     EISSN: 20056745     Source Type: Journal    
DOI: 10.4111/kju.2012.53.9.583     Document Type: Review

References (88)

1. Yoshimura N, de Groat WC. Neural control of the lower urinary tract. Int J Urol 1997;4:111-25.
2. de Groat WC. Integrative control of the lower urinary tract: preclinical perspective. Br J Pharmacol 2006;147 Suppl 2:S25-40.
3. Gulur DM, Drake MJ. Management of overactive bladder. Nat Rev Urol 2010;7:572-82.
4. Gormley EA. Urologic complications of the neurogenic bladder. Urol Clin North Am 2010;37:601-7.
5. Kwon T, Park J, Park MC, Han JY, Kim KS. Risk factors for upper urinary tract deterioration in children with neurogenic bladder. Korean J Urol 2009;50:1248-52.
6. Burney TL, Senapati M, Desai S, Choudhary ST, Badlani GH. Acute cerebrovascular accident and lower urinary tract dysfunction: a prospective correlation of the site of brain injury with urodynamic findings. J Urol 1996;156:1748-50.
7. Kong KH, Young S. Incidence and outcome of poststroke urinary retention: a prospective study. Arch Phys Med Rehabil 2000;81: 1464-7.
8. Marinkovic SP, Badlani G. Voiding and sexual dysfunction after cerebrovascular accidents. J Urol 2001;165:359-70.
9. Sakakibara R, Hattori T, Yasuda K, Yamanishi T. Micturitional disturbance after acute hemispheric stroke: analysis of the lesion site by CT and MRI. J Neurol Sci 1996;137:47-56.
10. Nakayama H, Jorgensen HS, Pedersen PM, Raaschou HO, Olsen TS. Prevalence and risk factors of incontinence after stroke. The Copenhagen Stroke Study. Stroke 1997;28:58-62.
11. Swaminath PV, Ragothaman M, Koshy S, Sarangmath N, Adhyam M, Subbakrishna DK, et al. Urogenital symptoms in Parkinson's disease and multiple system atrophy-Parkinsonism: at onset and later. J Assoc Physicians India 2010;58:86-90.
12. Campeau L, Soler R, Andersson KE. Bladder dysfunction and parkinsonism: current pathophysiological understanding and management strategies. Curr Urol Rep 2011;12:396-403.
13. Wenning GK, Colosimo C, Geser F, Poewe W. Multiple system atrophy. Lancet Neurol 2004;3:93-103.
14. Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008;71:670-6.
15. Köllensperger M, Geser F, Ndayisaba JP, Boesch S, Seppi K, Ostergaard K, et al. Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord 2010;25:2604-12.
16. Fowler CJ, Dalton C, Panicker JN. Review of neurologic diseases for the urologist. Urol Clin North Am 2010;37:517-26.
17. Bloch F, Pichon B, Bonnet AM, Pichon J, Vidailhet M, Roze E, et al. Urodynamic analysis in multiple system atrophy: characterisation of detrusor-sphincter dyssynergia. J Neurol 2010;257: 1986-91.
18. Uchiyama T, Sakakibara R, Yamamoto T, Ito T, Yamaguchi C, Awa Y, et al. Urinary dysfunction in early and untreated Parkinson's disease. J Neurol Neurosurg Psychiatry 2011;82: 1382-6.
19. Araki I, Kitahara M, Oida T, Kuno S. Voiding dysfunction and Parkinson's disease: urodynamic abnormalities and urinary symptoms. J Urol 2000;164:1640-3.
20. Sakakibara R, Hattori T, Uchiyama T, Yamanishi T. Videourodynamic and sphincter motor unit potential analyses in Parkinson's disease and multiple system atrophy. J Neurol Neurosurg Psychiatry 2001;71:600-6.
21. Pramstaller PP, Wenning GK, Smith SJ, Beck RO, Quinn NP, Fowler CJ. Nerve conduction studies, skeletal muscle EMG, and sphincter EMG in multiple system atrophy. J Neurol Neurosurg Psychiatry 1995;58:618-21.
22. Sakakibara R, Uchiyama T, Yamanishi T, Kishi M. Sphincter EMG as a diagnostic tool in autonomic disorders. Clin Auton Res 2009;19:20-31.
23. Cameron AP, Rodriguez GM, Schomer KG. Systematic review of urological followup after spinal cord injury. J Urol 2012;187: 391-7.
24. Jeong SJ, Cho SY, Oh SJ. Spinal cord/brain injury and the neurogenic bladder. Urol Clin North Am 2010;37:537-46.
25. Han SJ, Lee JE. Risk factors for urinary tract infection in chronic spinal cord injured patients. J Korean Acad Rehabil Med 2005;29:181-6.
26. Watanabe T, Rivas DA, Chancellor MB. Urodynamics of spinal cord injury. Urol Clin North Am 1996;23:459-73.
27. Sahai A, Cortes E, Seth J, Khan MS, Panicker J, Kelleher C, et al. Neurogenic detrusor overactivity in patients with spinal cord injury: evaluation and management. Curr Urol Rep 2011;12: 404-12.
28. Abrams P, Agarwal M, Drake M, El-Masri W, Fulford S, Reid S, et al. A proposed guideline for the urological management of patients with spinal cord injury. BJU Int 2008;101:989-94.
29. Krassioukov A, Warburton DE, Teasell R, Eng JJ; Spinal Cord Injury Rehabilitation Evidence Research Team. A systematic review of the management of autonomic dysreflexia after spinal cord injury. Arch Phys Med Rehabil 2009;90:682-95.
30. Rabchevsky AG, Kitzman PH. Latest approaches for the treatment of spasticity and autonomic dysreflexia in chronic spinal cord injury. Neurotherapeutics 2011;8:274-82.
31. Mourtzinos A, Stoffel JT. Management goals for the spina bifida neurogenic bladder: a review from infancy to adulthood. Urol Clin North Am 2010;37:527-35.
32. de Jong TP, Chrzan R, Klijn AJ, Dik P. Treatment of the neurogenic bladder in spina bifida. Pediatr Nephrol 2008;23:889-96.
33. Scales CD Jr, Wiener JS. Evaluating outcomes of enterocystoplasty in patients with spina bifida: a review of the literature. J Urol 2008;180:2323-9.
34. Daneshgari F, Moore C. Diabetic uropathy. Semin Nephrol 2006;26:182-5.
35. Gomez CS, Kanagarajah P, Gousse AE. Bladder dysfunction in patients with diabetes. Curr Urol Rep 2011;12:419-26.
36. Daneshgari F, Liu G, Birder L, Hanna-Mitchell AT, Chacko S. Diabetic bladder dysfunction: current translational knowledge. J Urol 2009;182(6 Suppl):S18-26.
37. Li WJ, Oh SJ. Diabetic cystopathy is associated with PARP/JNK/ mitochondrial apoptotic pathway-mediated bladder apoptosis. Neurourol Urodyn 2010;29:1332-7.
38. Li WJ, Shin MK, Oh SJ. Poly(ADP-ribose) polymerase is involved in the development of diabetic cystopathy via regulation of nuclear factor kappa B. Urology 2011;77:1265. e1-8.
39. Kaplan SA, Te AE, Blaivas JG. Urodynamic findings in patients with diabetic cystopathy. J Urol 1995;153:342-4.
40. Bansal R, Agarwal MM, Modi M, Mandal AK, Singh SK. Urodynamic profile of diabetic patients with lower urinary tract symptoms: association of diabetic cystopathy with autonomic and peripheral neuropathy. Urology 2011;77:699-705.
41. Dib PT, Trigo-Rocha F, Gomes CM, Srougi M. Urodynamic evaluation in diabetic patients with prostate enlargement and lower urinary tract symptoms. Urol Int 2008;80:378-82.
42. Benevento BT, Sipski ML. Neurogenic bladder, neurogenic bowel, and sexual dysfunction in people with spinal cord injury. Phys Ther 2002;82:601-12.
43. Ku JH. The management of neurogenic bladder and quality of life in spinal cord injury. BJU Int 2006;98:739-45.
44. Oh SJ, Ku JH, Jeon HG, Shin HI, Paik NJ, Yoo T. Health-related quality of life of patients using clean intermittent catheterization for neurogenic bladder secondary to spinal cord injury. Urology 2005;65:306-10.
45. Sauerwein D. Urinary tract infection in patients with neurogenic bladder dysfunction. Int J Antimicrob Agents 2002;19:592-7.
46. Shin JC, Yoo JH, Park JW, Park S, Ahn SJ, Park CI. Difference of organism and their antibiotics sensitivity from urine culture in symptomatic urinary tract infection of spinal cord injury patients. J Korean Acad Rehabil Med 2008;32:38-44.
47. Kelly CE. Evaluation of voiding dysfunction and measurement of bladder volume. Rev Urol 2004;6 Suppl 1:S32-7.
48. Dromerick AW, Edwards DF. Relation of postvoid residual to urinary tract infection during stroke rehabilitation. Arch Phys Med Rehabil 2003;84:1369-72.
49. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21: 167-78.
50. Bright E, Drake MJ, Abrams P. Urinary diaries: evidence for the development and validation of diary content, format, and duration. Neurourol Urodyn 2011;30:348-52.
51. Bright E, Cotterill N, Drake M, Abrams P. Developing a validated urinary diary: phase 1. Neurourol Urodyn 2012;31:625-33.
52. Ku JH, Jeong IG, Lim DJ, Byun SS, Paick JS, Oh SJ. Voiding diary for the evaluation of urinary incontinence and lower urinary tract symptoms: prospective assessment of patient compliance and burden. Neurourol Urodyn 2004;23:331-5.
53. McGuire EJ, Woodside JR, Borden TA, Weiss RM. Prognostic value of urodynamic testing in myelodysplastic patients. 1981. J Urol 2002;167(2 Pt 2):1049-53.
54. Bacsu CD, Chan L, Tse V. Diagnosing detrusor sphincter dyssynergia in the neurological patient. BJU Int 2012;109 Suppl 3:31-4.
55. Park JS, Park WH. The analysis of risk factors for upper urinary tract disease in spinal cord injured patients: including video urodynamic findings. Korean J Urol 2005;46:943-9.
56. Hyman MJ, Groutz A, Blaivas JG. Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol 2001;166:550-2.
57. Wyndaele JJ. Correlation between clinical neurological data and urodynamic function in spinal cord injured patients. Spinal Cord 1997;35:213-6.
58. Weld KJ, Dmochowski RR. Association of level of injury and bladder behavior in patients with post-traumatic spinal cord injury. Urology 2000;55:490-4.
59. Cameron AP. Pharmacologic therapy for the neurogenic bladder. Urol Clin North Am 2010;37:495-506.
60. Dorsher PT, McIntosh PM. Neurogenic bladder. Adv Urol 2012; 2012:816274.
61. Wyndaele JJ, Kovindha A, Madersbacher H, Radziszewski P, Ruffion A, Schurch B, et al. Neurologic urinary incontinence. Neurourol Urodyn 2010;29:159-64.
62. Koch T, Kelly S. Identifying strategies for managing urinary incontinence with women who have multiple sclerosis. J Clin Nurs 1999;8:550-9.
63. Winder A. Intermittent self-catheterisation. Nurs Times 2002; 98:50.
64. Oh SJ, Ku JH, Lim SH, Jeon HG, Son H. Effect of a 'centralized intensive education system' for clean intermittent self-catheterization in patients with voiding dysfunction who start catheterization for the first time. Int J Urol 2006;13:905-9.
65. Feifer A, Corcos J. Contemporary role of suprapubic cystostomy in treatment of neuropathic bladder dysfunction in spinal cord injured patients. Neurourol Urodyn 2008;27:475-9.
66. Ito T, Sakakibara R, Yasuda K, Yamamoto T, Uchiyama T, Liu Z, et al. Incomplete emptying and urinary retention in multiple-system atrophy: when does it occur and how do we manage it? Mov Disord 2006;21:816-23.
67. Katsumi HK, Kalisvaart JF, Ronningen LD, Hovey RM. Urethral versus suprapubic catheter: choosing the best bladder management for male spinal cord injury patients with indwelling catheters. Spinal Cord 2010;48:325-9.
68. Kennelly MJ, Devoe WB. Overactive bladder: pharmacologic treatments in the neurogenic population. Rev Urol 2008;10: 182-91.
69. Stöhrer M, Blok B, Castro-Diaz D, Chartier-Kastler E, Del Popolo G, Kramer G, et al. EAU guidelines on neurogenic lower urinary tract dysfunction. Eur Urol 2009;56:81-8.
70. Stöhrer M, Murtz G, Kramer G, Schnabel F, Arnold EP, Wyndaele JJ, et al. Propiverine compared to oxybutynin in neurogenic detrusor overactivity--results of a randomized, double-blind, multicenter clinical study. Eur Urol 2007;51:235-42.
71. Amend B, Hennenlotter J, Schafer T, Horstmann M, Stenzl A, Sievert KD. Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. Eur Urol 2008;53:1021-8.
72. Horstmann M, Schaefer T, Aguilar Y, Stenzl A, Sievert KD. Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage. Neurourol Urodyn 2006;25:441-5.
73. Bennett N, O'Leary M, Patel AS, Xavier M, Erickson JR, Chancellor MB. Can higher doses of oxybutynin improve efficacy in neurogenic bladder? J Urol 2004;171(2 Pt 1):749-51.
74. Aslan AR, Kogan BA. Conservative management in neurogenic bladder dysfunction. Curr Opin Urol 2002;12:473-7.
75. Wang P, Luthin GR, Ruggieri MR. Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins. J Pharmacol Exp Ther 1995;273: 959-66.
76. Cartwright PC, Coplen DE, Kogan BA, Volinn W, Finan E, Hoel G. Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity. J Urol 2009;182: 1548-54.
77. Kennelly MJ, Lemack GE, Foote JE, Trop CS. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study. Urology 2009;74:741-5.
78. Van Meel TD, De Wachter S, Wyndaele JJ. The effect of intravesical oxybutynin on the ice water test and on electrical perception thresholds in patients with neurogenic detrusor overactivity. Neurourol Urodyn 2010;29:391-4.
79. Michel MC, Vrydag W. Alpha1-, alpha2-and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 2006;147 Suppl 2:S88-119.
80. Consortium for Spinal Cord Medicine. Bladder management for adults with spinal cord injury: a clinical practice guideline for health-care providers. J Spinal Cord Med 2006;29:527-73.
81. Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol 2011;60:742-50.
82. Cruz CD, Cruz F. Spinal cord injury and bladder dysfunction: new ideas about an old problem. ScientificWorldJournal 2011;11: 214-34.
83. Duthie JB, Vincent M, Herbison GP, Wilson DI, Wilson D. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev 2011;(12):CD005493.
84. Mangera A, Andersson KE, Apostolidis A, Chapple C, Dasgupta P, Giannantoni A, et al. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol 2011;60:784-95.
85. Stein R, Schroder A, Thuroff JW. Bladder augmentation and urinary diversion in patients with neurogenic bladder: surgical considerations. J Pediatr Urol 2012;8:153-61.
86. Wiener JS, Antonelli J, Shea AM, Curtis LH, Schulman KA, Krupski TL, et al. Bladder augmentation versus urinary diversion in patients with spina bifida in the United States. J Urol 2011;186:161-5.
87. Biers SM, Venn SN, Greenwell TJ. The past, present and future of augmentation cystoplasty. BJU Int 2012;109:1280-93.
88. Austin JC. Long-term risks of bladder augmentation in pediatric patients. Curr Opin Urol 2008;18:408-12.